- Home
- WAFU vs GLTO Comparison
WAFU vs GLTO Comparison
Compare WAFU & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAFU
- GLTO
- Stock Information
- Founded
- WAFU 1999
- GLTO 2011
- Country
- WAFU China
- GLTO Denmark
- Employees
- WAFU N/A
- GLTO N/A
- Industry
- WAFU Other Consumer Services
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- WAFU Real Estate
- GLTO Health Care
- Exchange
- WAFU Nasdaq
- GLTO Nasdaq
- Market Cap
- WAFU 7.1M
- GLTO 6.5M
- IPO Year
- WAFU 2019
- GLTO 2020
- Fundamental
- Price
- WAFU $1.72
- GLTO $5.13
- Analyst Decision
- WAFU
- GLTO Buy
- Analyst Count
- WAFU 0
- GLTO 1
- Target Price
- WAFU N/A
- GLTO $10.00
- AVG Volume (30 Days)
- WAFU 392.4K
- GLTO 19.9K
- Earning Date
- WAFU 01-01-0001
- GLTO 03-07-2025
- Dividend Yield
- WAFU N/A
- GLTO N/A
- EPS Growth
- WAFU N/A
- GLTO N/A
- EPS
- WAFU N/A
- GLTO N/A
- Revenue
- WAFU $7,223,220.00
- GLTO N/A
- Revenue This Year
- WAFU N/A
- GLTO N/A
- Revenue Next Year
- WAFU N/A
- GLTO N/A
- P/E Ratio
- WAFU N/A
- GLTO N/A
- Revenue Growth
- WAFU N/A
- GLTO N/A
- 52 Week Low
- WAFU $1.46
- GLTO $4.40
- 52 Week High
- WAFU $2.85
- GLTO $23.50
- Technical
- Relative Strength Index (RSI)
- WAFU 54.31
- GLTO 47.84
- Support Level
- WAFU $1.56
- GLTO $4.60
- Resistance Level
- WAFU $1.76
- GLTO $5.98
- Average True Range (ATR)
- WAFU 0.13
- GLTO 0.40
- MACD
- WAFU 0.00
- GLTO 0.02
- Stochastic Oscillator
- WAFU 39.02
- GLTO 38.33
About WAFU Wah Fu Education Group Limited
Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services, and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.